Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies
Wanxiao Sun, Yaxin Deng, Meihui Zhao, et al.
Journal of Controlled Release (2021) Vol. 333, pp. 41-64
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles
Chunai Gong, Xiaoyan Yu, Wei Zhang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 89
RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy
Mehdi Sanati, Amir R. Afshari, Samaneh Aminyavari, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 84, pp. 104562-104562
Closed Access | Times Cited: 26
Nanotherapeutics for prostate cancer treatment: A comprehensive review
Ruimin Hu, Lan Jin, Dinglin Zhang, et al.
Biomaterials (2024) Vol. 305, pp. 122469-122469
Closed Access | Times Cited: 10
Rod-shaped nintedanib nanocrystals improved oral bioavailability through multiple intestinal absorption pathways
Yunjing Zhu, Yu Fu, Anan Zhang, et al.
European Journal of Pharmaceutical Sciences (2021) Vol. 168, pp. 106047-106047
Open Access | Times Cited: 44
Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer
Xiangle Zeng, Yawen Zhang, Xue Xu, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 792-806
Open Access | Times Cited: 37
Cyclodextrin-containing redox-responsive nanogels: Fabrication of a modular targeted drug delivery system
Aysun Degirmenci, Hazal Ipek, Rana Sanyal, et al.
European Polymer Journal (2022) Vol. 181, pp. 111645-111645
Closed Access | Times Cited: 35
Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
Xiujuan Liu, Xu-Liu, Xiaojing Pang, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 47, pp. 116358-116358
Closed Access | Times Cited: 33
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy
Mingze He, Yu Cao, Changliang Chi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Ferroptosis and ferroptosis-inducing nanomedicine as a promising weapon in combination therapy of prostate cancer
Mengjun Huang, Qiliang Teng, Fei Cao, et al.
Biomaterials Science (2024) Vol. 12, Iss. 7, pp. 1617-1629
Closed Access | Times Cited: 5
Recent Trends in Nanocarrier-Based Drug Delivery System for Prostate Cancer
Amit Kumar, Akshay Kumar Lunawat, Ashutosh Kumar, et al.
AAPS PharmSciTech (2024) Vol. 25, Iss. 3
Closed Access | Times Cited: 5
Advances in and prospects of immunotherapy for prostate cancer
Deng Liu, Luofu Wang, Yanli Guo
Cancer Letters (2024) Vol. 601, pp. 217155-217155
Open Access | Times Cited: 5
Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat
Mehdi Sanati, Amir R. Afshari, Seyed Sajad Ahmadi, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2023) Vol. 1869, Iss. 6, pp. 166720-166720
Closed Access | Times Cited: 12
Bibliometric analysis of glycolysis and prostate cancer research from 2004 to 2024
Congxu Zhu, Jingjing Yang, Lumei Liu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Nature's Warriors
Devender Singh, Pardeep Kumar Mehla, Bharat Bhushan Bahmani, et al.
IGI Global eBooks (2025), pp. 107-140
Closed Access
Identification and validation of a novel anoikis‐related prognostic model for prostate cancer
Peipei Zhang, Wenzhi Lv, Yang Luan, et al.
Molecular Genetics & Genomic Medicine (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 3
Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer
Jingyi Zhang, Lijie Zhao, Yatao Wang
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115925-115925
Closed Access | Times Cited: 8
Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer
Renjith P. Johnson, Chandrahas Koumar Ratnacaram, Lalit Kumar, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100865-100865
Closed Access | Times Cited: 13
TRIM11 Posttranscriptionally Modulated by miR-5193 Facilitates Tumor Growth and Metastasis of Prostate Cancer
Yue Pan, Hui Yu, Feng Lü
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 7
Reactive oxygen species produced by photodynamic therapy enhance docosahexaenoic acid lipid peroxidation and induce the death of breast cancer cells
Weiwei Bai, Yongyong Xue, Yiyan Guo, et al.
Colloids and Surfaces B Biointerfaces (2024) Vol. 241, pp. 114012-114012
Closed Access | Times Cited: 2
PSMA-targeted low-molecular double conjugates for diagnostics and therapy
Stanislav A. Petrov, Nikolay Y. Zyk, Aleksei E. Machulkin, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113752-113752
Closed Access | Times Cited: 14
Reports of Plant-Derived Nanoparticles for Prostate Cancer Therapy
Abdulrahman M. Elbagory, Rodney Hull, Mervin Meyer, et al.
Plants (2023) Vol. 12, Iss. 9, pp. 1870-1870
Open Access | Times Cited: 5
Lectins applied to diagnosis and treatment of prostate cancer and benign hyperplasia: A review
Benildo Sousa Cavada, Messias Vital Oliveira, Vinicius José Silva Osterne, et al.
International Journal of Biological Macromolecules (2021) Vol. 190, pp. 543-553
Open Access | Times Cited: 8
Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020
Kun Chen, Kehua Jiang, Lannan Tang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 6
Investigating the bioactive compounds from Capsicum annum as a probable alternative therapy for prostate cancer treatment: a structure-based drug design approach
Misbaudeen Abdul-Hammed, Ibrahim Olaide Adedotun, Ubeydat Temitope Ismail, et al.
Pure and Applied Chemistry (2024) Vol. 96, Iss. 5, pp. 719-742
Closed Access
Macromolecular NO‐Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer
Jiaxin Chen, Bing Zhao, Junhui Zou, et al.
Advanced Healthcare Materials (2022) Vol. 12, Iss. 6
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top